Phase Ia, ﬁrst-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers.

AbGn-107 - AbGenomics

https://meetinglibrary.asco.org/record/182181

Andrew H. Ko; Andrew L. Coveler; Benjamin L. Schlechter; Tanios S. Bekaii-Saab; Brian M. Wolpin; Jeffrey William Clark; Yi-Lin Cheng; Ting-Ying Cheng; Peter J. Langecker; Shih-Yao Lin

Dec 10, 2019